About Abbisko Therapeutics
Abbisko Therapeutics is a company based in Shanghai (China) founded in 2016. Abbisko Therapeutics has raised $263 million across 4 funding rounds from investors including CICC, The Carlyle Group and Warburg Pincus. The company has 226 employees as of December 31, 2024. Abbisko Therapeutics operates in a competitive market with competitors including Enliven Therapeutics, Nuvalent, Nura Bio, NewAmsterdam Pharma and Skyhawk Therapeutics, among others.
- Headquarter Shanghai, China
- Employees 226 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abbisko Cayman Limited
-
Annual Revenue
$70.36 M (USD)2494.53as on Dec 31, 2024
-
Net Profit
$3.95 M (USD)0as on Dec 31, 2024
-
EBITDA
$275.54 K (USD)0as on Dec 31, 2024
-
Total Equity Funding
$263 M (USD)
in 4 rounds
-
Latest Funding Round
$123 M (USD), Series D
Jan 08, 2021
-
Investors
CICC
& 15 more
-
Employee Count
226
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Abbisko Therapeutics
Abbisko Therapeutics is a publicly listed company on the HKEX with ticker symbol 2256 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Abbisko Therapeutics
Abbisko Therapeutics has successfully raised a total of $263M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $123 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Abbisko Therapeutics
Abbisko Therapeutics has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include CICC, The Carlyle Group and Warburg Pincus.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Multi-stage private equity investments are pursued across diverse sectors.
|
Locked | Locked | Locked |
Investor details for Abbisko Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Abbisko Therapeutics
Investment portfolio details for Abbisko Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Abbisko Therapeutics
Detailed financials for Abbisko Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abbisko Therapeutics Comparisons
Peer comparison for Abbisko Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Abbisko Therapeutics
Abbisko Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enliven Therapeutics, Nuvalent, Nura Bio, NewAmsterdam Pharma and Skyhawk Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for solid tumours and blood cancers
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| Locked | Locked | Locked |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
|
| Locked | Locked | Locked |
RNA-modifying drug candidates are developed for multiple disorders.
|
Detailed competitors of Abbisko Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abbisko Therapeutics
Complete news archive for Abbisko Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abbisko Therapeutics
Abbisko Therapeutics was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Abbisko Therapeutics is headquartered in Shanghai, China.
Abbisko Therapeutics is a funded company, having raised a total of $263M across 4 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Abbisko Therapeutics is 226.
Annual revenue of Abbisko Therapeutics is $70.36M as on Dec 31, 2024.
Abbisko therapeutics is developing novel small molecule drugs for immunomodulatory pathways to treat cancer. The companys pipeline has three preclinical candidates. The exact mechanism of action of each moleule has not been disclosed but the company is possibly advancing a STINGTLR activator, IDOCSF1R inhibitor and TGF agonist. The companys integrated RD center locates in the Shanghai Zhangjiang Hi-Tech Park. The company claims to be surrounded by numerous top CRO, CMO and clinical contract organizations in the area, with whom they collaborate o research in drug discovery and development. In the future, the company aims to target other diseases such as liver disease, viral infections and mental disease.
Abbisko Therapeutics's top competitors include Nuvalent, Enliven Therapeutics and Nura Bio.
Yes, Abbisko Therapeutics is publicly traded on HKEX under the ticker symbol 2256.
Abbisko Therapeutics has 16 investors. Key investors include CICC, The Carlyle Group, Warburg Pincus, Orbimed, and Temasek.
The ticker symbol of Abbisko Therapeutics is 2256 on HKEX.